Overview

Rich-Henry is a member of the Intellectual Property Practice Group and practices as a registered patent attorney before the U.S. Patent & Trademark Office. An extensive background in biomedical science and biotechnology, including a Ph.D. in microbiology and immunology, enables him to bring a meticulous, detail-oriented approach to protecting clients’ intellectual property.

Rich-Henry handles all aspects of patent prosecution and counseling on behalf of clients and has experience in patent preparation, patent prosecution, post-grant proceedings, and development/management of patent portfolios in the U.S. and abroad. Rich-Henry is experienced in opinion work, including freedom to operate, validity, infringement, patent landscape, and patentability opinions. Technical areas of his prosecution and opinion work include all areas of biotechnology (including immunology, cell and molecular biology, virology, bacteriology, genetics, and biochemistry), medical devices, the chemical arts, and pharmaceuticals.

Rich-Henry has acted as a technical liaison between trial counsel and expert witnesses during a multimillion-dollar medical device litigation and served as counsel on a team defending a series of biotechnology patents of a Fortune 500 company in Inter Partes Review proceedings before the U.S. Patent & Trademark Office.

Prior to joining Adler Pollock & Sheehan, Rich-Henry worked at Dinsmore & Shohl.

In addition to his law practice, Rich-Henry worked on the development of novel vaccine adjuvant systems at the Institute of Cellular Therapeutics at the University of Louisville School of Medicine. Additionally, Rich-Henry previously served as an AmeriCorps Team Leader, where he further developed his leadership and management abilities.

Education

Brandeis School of Law at the University of Louisville (J.D., cum laude, NEED YEAR)

University of Louisville School of Medicine (Ph.D., 2010)

University of Louisville School of Medicine (M.S., 2006)

University of Virginia (B.A., 2005)

Admissions

Kentucky

U.S. Patent & Trademark Office

Not licensed to practice in Rhode Island

Representative Matters
  • Drafted over 40 international or U.S. non-provisional patent applications related to biotechnology.
  • Development/management of patent portfolios in the U.S. and abroad and prosecuted over 75 patent applications in a variety of technical areas, including biotechnology, the chemical arts, and medical devices.
  • Drafted over 40 patentability, freedom to operate, validity, infringement, and patent landscape opinions related to pharmaceuticals, biotechnology, and medical devices.
  • Acted as a technical liaison between trial counsel and expert witnesses during a multimillion-dollar medical device litigation.
  • Counsel on a team defending a series of biotechnology patents in Inter Partes Review proceedings before the USPTO.
Seminars / Publications
  • Madireddi S, Schabowsky RH, et al. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+FoxP3+ T regulatory cells by production of IFN-γ. Plos One. 2012; 7(8):e42459.
  • Schabowsky RH*, et al. A novel form of 4-1BBL as a multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Research. 2010, 70(10): 3945-54. *shared first author
  • Sharma RK, Srivastava AK, Yolcu ES, Schabowsky RH & Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse model of cervical cancer. Vaccine. 2010, 28(36): 5794-802.
  • Schabowsky RH, et al. A novel form of 4-1BBL has better immunomodulatory activity than an agonist anti-4-1BB Ab without Ab associated severe toxicity. Vaccine. 2009, 28(2): 512-22.
  • Schabowsky RH, et al. ProtExTM technology for the generation of novel therapeutic cancer vaccines. Journal of Experimental Pathology. 2009, 86(3): 198-207.
  • Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Mittler RS, & Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Research. 2009, 69(10): 4319-4326.
  • Schabowsky RH, et al. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs. 2007, 8(12): 1002-8.
  • Elpek KG, Yolcu ES, Franke DD, Lachelle C, Schabowsky RH, & Shirwan, H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of Immunology. 2007, 179(11):7295-304.
Professional Affiliations
  • IPO Pharmaceutical & Biotechnology Issues Committee
  • Member, Kentucky Bar Association
In the Community
  • Volunteer, Manual High School Student Science Fair Project, Louisville, KY (2008-2009).
  • Team Leader and Volunteer, Project Jumpstart/AmeriCorps Team Leader, Charlottesville, VA (2004 – 2005).

Pro Bono Work

                Kentucky Science Center, Louisivlle, KY 

  • Assisted the Kentucky Science Center in various licensing agreements, procurement of various trademarks, and in the negotiation of a settlement agreement with a potential infringer of those trademarks.
Print PDF
Back to Top